10-04 :: April 2010
nanotimes
Companies
Facts
several months and over 50% for the year, we are lucky there are many talented people in the valley looking for a high growth opportunity at this time,” said Lex Kosowsky, President and CEO.
Shocking Technologies, Inc. is a privately held, venture-backed company developing Voltage Swit- chable Dielectric™ (VSD™) materials. A VSD™ mate- rial is a polymer nano-composite that behaves like an insulator (dielectric) during normal circuit operation and becomes conductive when the voltage across the VSDTM material increases beyond a predefined threshold voltage. After the voltage drops below the threshold again, it switches back to an insulator.
http://www.shockingtech.com
S
hrink Nanotechnologies, Inc. (OTCBB: INKN), an innovative nanotechnology company deve-
loping products and licensing opportunities in the solar energy production, medical diagnostics, sensors and biotechnology research and development tools businesses, announced that FINRA has approved a common stock forward split of 5 for 1. For a period of 20 business days, the Company’s stock symbol will be “INKND.” On the 21st business day subsequent to the 15th of April, 2010, the Company’s stock symbol will revert back to its present stock symbol of “INKN.”
The forward split will be “payable upon surrender” of existing common stock to the Company’s transfer agent, Action Stock Transfer. Following the forward stock split, there will be approximately 191,303,985 issued and outstanding common shares. Shrink‘s products are based on a pre-stressed plastic called NanoShrink™, and on a patent-pending manufac- turing process called the ShrinkChip Manufacturing
Solution™. Furthermore, Shrink announced that its proprietary NanoShrink™ material has shown to produce superior microfluidic and point-of-care test prototypes in a landmark study conducted by the University of California Irvine‘s (UCI) Department of Biomedical Engineering, USA. The UCI findings were published in “Lab on a Chip”.
Diep Nguyen, Douglas Taylor, Kun Qian, Nizilla Norouzi, Jerald Rasmussen, Steve Botzet, Matt Lehmann, Kurt Hal- verson and Michelle Khine: Better shrinkage than Shrinky- Dinks, In: Lab Chip AOP, March 24, 2010, DOI:10.1039/ c001082k:
http://dx.doi.org/ 10.1039/c001082k
http://www.shrinknano.com
S
loning, leading supplier of synthetic biology tools, was awarded US Patent No, 7,695,906. Sloning’s enabling platform technology – Slonomics®
– allows
researchers to increase the success rate of their scree- ning for new and optimized therapeutic antibodies, proteins or industrial enzymes.
Key to Sloning’s success is the company’s core tech- nology, Slonomics®
, a patented technology that uses
a set of double stranded DNA triplets as universal building blocks for the synthesis of combinatorial libraries – “one codon at a time”. For library produc- tion, multiple codons can be introduced in parallel at any desired sequence position. The absence of functional bias and the ability to select and precisely control delivery of up to 20 codons at any ratio re- sults in exceptionally high quality libraries containing the complete set of desired mutants. In addition, mutated regions of varying length can also be incor- porated in the design.
http://www.sloning.com
35
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87